Peptides DB
Research-centric peptide and protocol reference hub
Study 1 of 6Octreotide literaturebiorxiv-preprint · Case report2026

Acute Promyelocytic Leukaemia Presenting as Bleeding in a Minor Burn Patient: A Case Report

In burn patients with severe cytopaenias, consider alternative diagnoses like acute promyelocytic leukaemia, as peripheral blood smear analysis can be crucial.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the octreotide corpus
0
Preclinical
5
Observational · this one
0
Open-label
0
Randomised
1
Reviews

Summary and findings

This case report discusses a 12-year-old female burn patient who presented with severe gastrointestinal bleeding and cytopaenias after a minor burn. Investigations revealed acute promyelocytic leukaemia, confirmed by fluorescence in situ hybridisation. Despite management, the patient developed multiorgan failure and died.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.2026

Abstract

The authors’ words, as biorxiv-preprint supplied them

<h4>Background: </h4> and Clinical Significance: When burn patients develop cytopaenias, particularly thrombocytopaenia and anaemia, the aetiology is often multifactorial but usually linked to either systemic inflammatory response syndrome (SIRS) or wound sepsis. However, haematological derangements that are disproportionate to the burn severity pose a critical red flag and should raise suspicion for alternative pathology. The potential value of peripheral blood smear analysis in identifying alternative haematological pathologies in burn patients with unexpectedly severe cytopaenias is discussed. Case Presentation: We report a retrospective case review of a 12 year old female without co-morbidities, who sustained a minor 4% total body surface area scald burn and presented to a Burn Unit with severe gastrointestinal bleeding, thrombocytopaenia, anaemia, and leucocytosis unresponsive to conventional medical therapy. Investigations included gastroscopy, thromboelastography, blood cultures, and peripheral blood smear analysis. Management included fluid resuscitation, blood transfusions, antibiotics, pantoprazole, octreotide, and renal replacement therapy. The unexpectedly severe cytopaenia and poor response to transfusion support prompted peripheral blood smear analysis, which revealed findings consistent with acute promyelocytic leukaemia , confirmed by fluorescence in situ hybridisation demonstrating t(15;17) and PML/RARA fusion. The patient was commenced on All-Trans Retinoic Acid and Daunorubicin. Despite intensive multidisciplinary management, the patient developed multiorgan failure and died. <h4>Conclusions:</h4> This case illustrates how peripheral blood smear analysis helped identify an underlying haematological malignancy in a burn patient with unexpectedly severe or disproportionate cytopaenias, underscoring the importance of a broad differential diagnosis in this clinical context.

Elsewhere in the Octreotide corpus

BEx Vivo Drug Sensitivity in Patient-derived 3D Cultures in Acromegaly and its Association with Clinical Predictorsbiorxiv-preprint · 2026 · Median cell viability reduction of 84-86%, p < 0.05.HumanDCarcinoid Heart Disease: Surgical Timing, Right Ventricular Risk Stratification and Operative Strategybiorxiv-preprint · 2026 · 5–6% operative mortality in contemporary high-volume centres.BManagement of Chylous Acid in Gynecological Malignanciesbiorxiv-preprint · 2026 · 830 mL on POD 4 serves as a significant clinical predictor for standardizing the timing of advanced conservative intervention.HumanBSurgical management and risk factors of chylothorax following congenital heart surgerybiorxiv-preprint · 2026 · Chylothorax resolved in 53 patients (82.8%) through conservative management, n=64.HumanBElimination Capacity Determines Outcome in Amatoxin Mushroom Poisoning-Induced Acute Liver Failure: A Globally Applicable Management Frameworkbiorxiv-preprint · 2026 · Transplant-free recovery: 98.8% among protocol-adherent patients (n=86).Human